The neuroscience partnership announced in April 2004 between Solvay and Wyeth has already resulted in a new drug application for bifeprunox for the treatment of patients with schizophrenia. Meanwhile, development continues on two other early phase neuroscience projects SLV313 and SLV314, which were part of that agreement.
Under the new agreement, the parties will collaborate in a joint discovery effort targeting the identification of small molecules with the potential to be used as anti-psychotic medications. Any compounds discovered under this research collaboration will be co-owned by Solvay and Wyeth and could be selected for development and commercialization by both companies.
“Combining Solvay's experience with that of Wyeth could enable the discovery of novel candidate molecules in an expanded chemical space now based on joint knowledge,” said Professor Les Turski, global vice president of Research for Solvay Pharmaceuticals.
The parties will initially contribute several molecules each into this collaboration, and thereafter dedicate equal resources to the research efforts. There are no signing fees or milestone payments associated with this agreement.